REQUEST A DEMO
Total
USD $0.00
Search more companies

Evropa Lek Pharma D.O.O. Beograd (Serbia)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers
Full name: Evropa Lek Pharma D.O.O. Beograd Profile Updated: June 12, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

Evropa Lek Pharma was set up in 2000 and is part of pharmaceutical trading company Phoenix Group. The firm is active in medicines and medical equipment wholesale and it also provides support services for registration, logistics and marketing of pharmaceuticals.

Headquarters
Bore Stankovica 2
Beograd-Cukarica; Beograd-Cukarica; Postal Code: 11030

Contact Details: Purchase the Evropa Lek Pharma D.O.O. Beograd report to view the information.

Website: http://www.elpharma.com

Basic Information
Total Employees:
Purchase the Evropa Lek Pharma D.O.O. Beograd report to view the information.
Outstanding Shares:
Purchase the Evropa Lek Pharma D.O.O. Beograd report to view the information.
Registered Capital:
Purchase the Evropa Lek Pharma D.O.O. Beograd report to view the information.
Financial Auditors:
Purchase the Evropa Lek Pharma D.O.O. Beograd report to view the information.
Incorporation Date:
October 22, 2000
Key Executives
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Representative
Ownership Details
Purchase this report to view the information.
100%
Subsidiaries
Phoenix It Services
100%
Company Performance
Financial values in the chart are available after Evropa Lek Pharma D.O.O. Beograd report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency RSD. Absolute financial data is included in the purchased report.
Net sales revenue
23.12%
Total operating revenue
23.2%
Operating profit (EBIT)
16.33%
EBITDA
15.79%
Net Profit (Loss) for the Period
57.44%
Total assets
23.79%
Total equity
28.21%
Operating Profit Margin (ROS)
-0.42%
Net Profit Margin
2.61%
Return on Equity (ROE)
6.64%
Debt to Equity Ratio
-1.63%
Quick Ratio
-0%
Cash Ratio
-0.06%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?